Allarity Therapeutics has developed a new Drug Response Predictor (DRP®) for daratumumab that can identify multiple myeloma patients most likely to benefit from treatment, as presented at AACR 2025.
Allarity Therapeutics is expanding its Phase 2 clinical trial of stenoparib for advanced ovarian cancer, aiming to optimize dosing and patient selection.
Allarity Therapeutics reports that two patients with advanced ovarian cancer have remained on stenoparib treatment for over 14 months in a Phase 2 trial.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.